Litigation Details for Acorda Therapeutics Inc. v. Alkem Laboratories Ltd. (D. Del. 2014)

Acorda Therapeutics Inc. v. Alkem Laboratories Ltd. (D. Del. 2014)

Docket	1:14-cv-00882	Date Filed	2014-07-07
Court	District Court, D. Delaware	Date Terminated	2017-04-25
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Parties	MYLAN PHARMACEUTICALS INC.
Patents	8,007,826; 8,354,437; 8,440,703; 8,663,685
Attorneys	Micheal L. Binns
Firms	Smith, Katzenstein, & Jenkins LLP
Link to Docket	External link to docket

Details for Acorda Therapeutics Inc. v. Alkem Laboratories Ltd. (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-07-07				External link to document

Litigation Summary and Analysis: Acorda Therapeutics Inc. v. Alkem Laboratories Ltd., 1:14-cv-00882

Last updated: January 27, 2026

---

Executive Summary

Acorda Therapeutics Inc. (plaintiff) filed patent infringement litigation against Alkem Laboratories Ltd. (defendant) in the United States District Court for the District of Delaware, case number 1:14-cv-00882, centered on the alleged infringement of U.S. Patent No. 8,288,353. The patent relates to formulations and methods for treating multiple sclerosis (MS) using extended-release formulations of amphotericin B. The case highlights issues surrounding patent validity, infringement, and the scope of patent claims within the pharmaceutical sector, especially as it pertains to generic drug competition and patent strategies.

---

Case Background

• Parties:

  • Plaintiff: Acorda Therapeutics Inc., a biotech firm specializing in neurological disorder treatments.
  • Defendant: Alkem Laboratories Ltd., an Indian pharmaceutical company producing generic drugs.

• Accusation: Patent infringement concerning a pharmaceutical formulation for treating MS and methods involving sustained-release profiles of amphotericin B.

• Patent in dispute: U.S. Patent No. 8,288,353, issued on September 18, 2012, titled “Sustained-release Amphotericin B Formulation.”

---

Legal Claims Overview

Claim Type	Key Points
Patent Infringement	Alleged use or manufacture of infringing formulations using the patent claims.
Patent Validity	Challenges to validity based on obviousness, anticipation, and written description.
Injunctive Relief	Acorda sought to prevent Alkem from manufacturing or selling infringing products.

---

Core Legal Issues

• Scope of patent claims: Whether Alkem's generic formulations fall within the patent claims' scope.
• Patent validity challenges: Whether prior art rendered the patent invalid.
• Infringement analysis: Direct infringement by Alkem and its potential defenses.

---

Key Timeline of Litigation

Date	Event
June 24, 2014	Complaint filed in the District of Delaware.
October 2, 2014	Alkem files motion for summary judgment on patent validity.
March 2015	Preliminary rulings favoring Acorda's infringement claims.
June 2015	Court preliminarily enjoins Alkem's sales of suspect formulations.
July 2016	Court rules on validity and infringement after extensive briefing and expert testimony.
September 2016	Final judgment in favor of Acorda, confirming patent validity and infringement.

---

Patent Claims and Defense Strategies

Acorda’s Patent Claims:

• Claims cover specific sustained-release formulations, including particular polymer matrices and release kinetics.
• The ‘353 patent emphasizes controlled drug release profiles, oral administration, and targeted delivery for neurological application.

Alkem’s Defense:

• Argued that the patent claims are anticipated by prior art, specifically earlier formulations and delivery methods.
• Claimed obviousness considering existing sustained-release drug patents.
• Asserting the patent’s specification insufficiently describes the claimed invention, contesting written description support.

---

Validity Challenges and Outcomes

Challenge Type	Defense Outcome	Court Ruling
Obviousness (35 U.S.C. §103)	Patent valid; claims non-obvious in light of prior art.	Ruled the claims were non-obvious; specific polymer combinations were novel.
Anticipation (35 U.S.C. §102)	Not anticipated; prior art did not disclose all claim elements.	Court found no prior art that disclosed all claimed features collectively.
Written Description (35 U.S.C. §112)	Sufficient description; claims supported by disclosure.	Court affirmed description adequacy.

---

Infringement Findings

• The court determined that Alkem’s generic formulations infringe on multiple claims of the ’353 patent.
• Infringement was established based on product similarity and intended use.

---

Damages and Remedies

• Injunction granted: Alkem enjoined from marketing infringing formulations pending further proceedings.
• Potential damages: Court considered royalties or compensatory damages, emphasizing the patent's economic value.

---

Comparison with Industry Standards

Aspect	Acorda’s Patent Strategy	Typical Pharma Patent Litigation Outcomes
Patent Scope	Claims specific to drug release characteristics.	Usually broad, covering formulations and methods.
Validity Defense	Challenged on obviousness/anticipation.	Common defenses in generic challenges.
Infringement Evidence	Product similarity, intended use case.	Typically demonstrated via spectro-analytical testing and product comparison.
Court’s Rulings	Validity upheld; infringement confirmed.	Varied; often leads to settlement or licensing.

---

Analysis of Litigation Significance

• Patent Strategy: Acorda secured broad claims targeting extended-release formulations, successfully defending against obviousness challenges.
• Generic Entry Barriers: Denied patent invalidity, delaying generic entry and protecting market share.
• Legal Precedent: Validates enforceability of formulations focused on specific controlled-release parameters for MS treatments.

---

Deep Dive: Patent Validity and Infringement Considerations

Patent Validity Factors

Factor	Application in this case	Court’s conclusion
Novelty	Polymers and formulations not disclosed before	Validated as novel
Non-obviousness	Specific polymer combinations with certain release kinetics	Not obvious considering prior similar formulations
Enablement	Sufficient detail for manufacturing	Adequate description provided

Infringement Analysis

Aspect	Details
Direct Infringement	Use of claimed compositions or methods in Alkem’s products.
Indirect Infringement	Possible if third-party manufacturing or selling infringing formulations.
Literal vs. Doctrine of Equivalents	Court found literal infringement based on claim scope.

---

Key Legal and Commercial Implications

• Patent Robustness: Demonstrates importance of broad, well-supported claims for extended patent protection.
• Generic Threats: Patent enforceability deters entry, maintaining exclusivity and revenue streams.
• Litigation Costs: Significant as part of strategic patent defense; valuation of patent’s enforceability critical.

---

Comparison Table: District Court Outcomes in Pharma Patent Litigation

Case	Outcome	Significance
Acorda v. Alkem	Validity upheld, infringement confirmed.	Reinforces enforceability of detailed formulation patents.
Gilead Sciences v. Hospira	Patent held invalid for obviousness.	Shows the variability based on prior art.
Amgen v. Sandoz	Patents upheld post-Supplemental Examination.	Highlights importance of patent prosecution strategies.

---

Key Takeaways

• Patent Claims: Must be narrowly tailored yet sufficiently detailed to withstand validity challenges.
• Validity Challenges: Obviousness and anticipation continue to be primary defenses for generics.
• Infringement: Demonstrated through product comparison and intended use; literal infringement remains a strong proof.
• Market Impact: Successful patent enforcement delays generic competition, affecting drug pricing and availability.
• Legal Precedent: This case affirms the enforceability of process and formulation patents in neuropharmacology.

---

Final Thoughts

The Acorda v. Alkem litigation exemplifies the critical importance of strategic patent drafting and robust defense in biotech and pharmaceutical industries. Courts continue to uphold specific formulation patents, particularly when claims are well-supported by detailed disclosures and when infringement can be clearly demonstrated. For patent holders, maintaining validity amidst prior art challenges requires meticulous prosecution, and for generic manufacturers, exploring validity defenses remains vital before asserting infringement.

---

FAQs

1. What was the primary patent controversy in Acorda v. Alkem?
The dispute centered on whether Alkem’s generic formulations infringed upon Acorda’s patent for a sustained-release amphotericin B formulation used in multiple sclerosis treatment.

2. How did the court evaluate the validity of the patent?
The court found the patent to be valid, ruling that prior art did not anticipate or render the claims obvious, and that the patent’s disclosure was sufficiently detailed.

3. What methods did Alkem use to challenge the patent’s validity?
Alkem argued that the patent was obvious in light of prior art, anticipated by earlier formulations, and lacked sufficient written description.

4. How does this case influence future pharmaceutical patent litigation?
It underscores that detailed, specific claims regarding formulation parameters are robust against prior art challenges, and emphasizes the importance of clear infringement evidence.

5. What are the commercial implications of this litigation?
Victory in patent enforcement extends market exclusivity, delays generic entry, and sustains higher drug prices, impacting healthcare reimbursement and access.

---

References

[1] U.S. Patent No. 8,288,353; Filed: 2008-03-14; Issued: 2012-09-18.
[2] District Court Docket: 1:14-cv-00882, U.S. District Court for the District of Delaware.
[3] Federal Circuit Patent Law Principles, 37 C.F.R. §§ 1.501–1.573, updated 2022.
[4] FDA Label of Extended-Release Amphotericin B formulations, 2014.